+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report

  • PDF Icon

    Report

  • 356 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 2227999

Global Acute Myeloid Leukemia (AML) Therapeutics Market to Reach $1.6 Billion by 2030

The global market for Acute Myeloid Leukemia (AML) Therapeutics estimated at US$587.6 Million in the year 2022, is projected to reach a revised size of US$1.6 Billion by 2030, growing at a CAGR of 13.4% over the analysis period 2022-2030. Cytarabine, one of the segments analyzed in the report, is projected to record 15.6% CAGR and reach US$571.6 Million by the end of the analysis period. Growth in the Anthracycline Drugs segment is estimated at 14.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $217.3 Million, While China is Forecast to Grow at 15.4% CAGR

The Acute Myeloid Leukemia (AML) Therapeutics market in the U.S. is estimated at US$217.3 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$151 Million by the year 2030 trailing a CAGR of 15.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12% and 12.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12.9% CAGR.

Select Competitors (Total 112 Featured)

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AbbVie, Inc.
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Actinium Pharmaceuticals, Inc.
  • Aptose Biosciences, Inc.
  • Aprea Therapeutics
  • Astex Pharmaceuticals, Inc.
  • AB Science SA
  • Aptevo Therapeutics
  • Ascentage Pharma
  • arGEN-X
  • Accent Therapeutics
  • Arcellx
  • Amphivena Therapeutics

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

What`s New?

  • Special discussions on the global economic climate and market sentiment
  • Coverage on global competitiveness and key competitor percentage market shares
  • Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and trademarked research platform
  • Complimentary updates for one year
  • Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
Frequently Asked Questions about the Acute Myeloid Leukemia (AML) Therapeutics Market

What is the estimated value of the Acute Myeloid Leukemia (AML) Therapeutics Market?

The Acute Myeloid Leukemia (AML) Therapeutics Market was estimated to be valued at $587.6 Million in 2022.

What is the growth rate of the Acute Myeloid Leukemia (AML) Therapeutics Market?

The growth rate of the Acute Myeloid Leukemia (AML) Therapeutics Market is 13.3%, with an estimated value of $1600 Million by 2030.

What is the forecasted size of the Acute Myeloid Leukemia (AML) Therapeutics Market?

The Acute Myeloid Leukemia (AML) Therapeutics Market is estimated to be worth $1600 Million by 2030.

Who are the key companies in the Acute Myeloid Leukemia (AML) Therapeutics Market?

Key companies in the Acute Myeloid Leukemia (AML) Therapeutics Market include Amgen, Inc., Astellas Pharma, Inc., AbbVie, Inc., A. Menarini Industrie Farmaceutiche Riunite Srl, Actinium Pharmaceuticals, Inc., Aptose Biosciences, Inc., Aprea Therapeutics, Astex Pharmaceuticals, Inc., AB Science SA and Aptevo Therapeutics.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • COVID-19 IMPACT AND THE LOOMING RECESSION
  • COVID-19’s Impact on Cancer Patients
  • Making the Cancer Patient Survive the Lethal Covid-19 Wave
  • Post-Covid-19 Complications to Affect Future Cancer Treatment
  • The Evolving Model of Care - Virtual/ Telemedicine Consultations
  • The Evolving Model of Care - Extending Care through Innovative Means
  • Pandemic Causes Delays in Procedures and Treatment
  • In-Office Cancer Patient Visits Decline amidst Pandemic
  • Vaccine Availability Comforts Cancer Patients
  • COVID-19 IMPACT ON ACUTE MYELOID LEUKEMIA THERAPEUTICS
  • Pandemic Caused Delays Impact AML Patients
  • Pandemic Related Issues Affect Oncology Research
  • Competition
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Acute Myeloid Leukemia (AML) Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
  • LEUKEMIA - A DISEASE OF THE BONE MARROW
  • A Prelude to Acute Myeloid Leukemia (AML)
  • Acute Myeloid Leukemia: Epidemiology
  • Acute Myeloid Leukemia (AML) Types
  • The FAB Classification of AML
  • WHO AML Classification
  • Etiology of AML
  • AML Symptoms
  • GLOBAL MARKET OUTLOOK AND PROSPECTS
  • Acute Myeloid Leukemia (AML) Therapeutics Market Primed for Massive Growth with Rising Patient Count & Promising Research Efforts
  • Drug Development Efforts Set Pace for Global Market
  • New Therapies Introduced in the Landscape
  • RECENT LAUNCHES IN THE AML MARKET
  • North America Maintains Leadership Position in Global Market
  • Chemotherapy: The Standard Mode of Treatment for AML Over the Years
  • Emerging Drug Therapies/Targeted Therapies for Acute Myeloid Leukemia to Drive the Market
  • FLT3 Inhibitors & Cytarabine: Bright Segments of Acute Myeloid Leukemia Therapeutics Market
  • Global FLT3 Inhibitors Market: Annual Sales in US$ Million for Years 2020 through 2027
  • EXISTING & POTENTIAL TREATMENT/THERAPEUTIC TARGETS FOR ACUTE MYELOID LEUKEMIA
  • Chemotherapy
  • AML Treatment
  • Stem Cell Transplant for Acute Myeloid Leukemia (AML)
  • Targeted Therapies Drive the Future of AML Market
  • ISOCITRATE DEHYDROGENASES (IDH)
  • BCL-2 Inhibitor
  • FLT3
  • Hedgehog (Hh)
  • Immunotherapy-Oriented Treatments
  • Neurotransmitter Receptors
  • Epigenetic Modulators
  • Organelle-Directed Strategies
  • New Formulations Using Existing Options
  • Antibody-Drug Conjugate Therapy for Acute Leukemia
  • Competitive Environment of AML Market
  • Targeted Therapies Market for AML by Product Class: Market Size Estimates in USD Million for 2020
  • Targeted Therapies Market for AML (2020) by Leading Drugs: Market Share of Revenues
  • RECENT MARKET ACTIVITY
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • High Incidence and Prevalence Drive Market Growth
  • Ballooning Elderly Population: The Vital Growth Driver for AML Therapeutics
  • Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
  • Life Expectancy for Select Countries in Number of Years: 2019
  • Advancements in Pharmacology & Molecular Biology to Promote AML Drug Development
  • Recent Drug Approvals
  • Rising Investments in AML Therapeutics R&D Augurs Well
  • Changing Face of Combination Therapies Improve Outcomes for treated Secondary AML
  • University of Texas’ Combination Therapy Study Shines Light at the end of Tunnel for Acute Myeloid Leukemia
  • Need for Better Treatments Entrenches Proteomics at Center of Acute Myeloid Leukemia Therapeutics R&D
  • Antibody-Oriented Protein Microarrays
  • AML - A Medical Challenge with High Relapse Rate
  • Therapeutic Landscape for Refractory/Relapsed Acute Myeloid Leukemia
  • Advances Related to FLT3 Inhibitors
  • Gilteritinib to Set New Therapeutic Paradigm for Acute Myeloid Leukemia
  • Novel Combination Therapies for Relapsed or Refractory AML
  • Novel Therapies for Treatment of Pediatric Relapsed AML
  • Immunotherapy Research for AML
  • Monoclonal Antibody (Mylotarg) - A Promising Drug
  • Chemotherapy Complications to Hinder the AML Market Growth
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 3: World 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Cytarabine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Cytarabine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 6: World 16-Year Perspective for Cytarabine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Anthracycline Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Anthracycline Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 9: World 16-Year Perspective for Anthracycline Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 12: World 16-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 15: World 16-Year Perspective for Alkylating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 18: World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Anti-Metabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Anti-Metabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 21: World 16-Year Perspective for Anti-Metabolites by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Other Chemotherapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Other Chemotherapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 24: World 16-Year Perspective for Other Chemotherapy Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 25: World Acute Myeloid Leukemia (AML) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030
  • CANADA
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 31: Canada 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030
  • JAPAN
  • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • TABLE 32: Japan Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 33: Japan Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 34: Japan 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030
  • CHINA
  • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • TABLE 35: China Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 36: China Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 37: China 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030
  • EUROPE
  • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • TABLE 38: Europe Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 39: Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 40: Europe 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
  • TABLE 41: Europe Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 42: Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 43: Europe 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030
  • FRANCE
  • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • TABLE 44: France Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 45: France Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 46: France 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030
  • GERMANY
  • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • TABLE 47: Germany Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 48: Germany Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 49: Germany 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030
  • ITALY
  • TABLE 50: Italy Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 51: Italy Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 52: Italy 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
  • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • TABLE 53: UK Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 54: UK Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 55: UK 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030
  • SPAIN
  • TABLE 56: Spain Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 57: Spain Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 58: Spain 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030
  • RUSSIA
  • TABLE 59: Russia Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 60: Russia Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 61: Russia 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030
  • REST OF EUROPE
  • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 63: Rest of Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 64: Rest of Europe 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
  • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 66: Asia-Pacific Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 67: Asia-Pacific 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
  • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 69: Asia-Pacific Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 70: Asia-Pacific 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030
  • AUSTRALIA
  • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
  • INDIA
  • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
  • MIDDLE EAST
  • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
  • AFRICA
  • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AbbVie, Inc.
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Actinium Pharmaceuticals, Inc.
  • Aptose Biosciences, Inc.
  • Aprea Therapeutics
  • Astex Pharmaceuticals, Inc.
  • AB Science SA
  • Aptevo Therapeutics
  • Ascentage Pharma
  • arGEN-X
  • Accent Therapeutics
  • Arcellx
  • Amphivena Therapeutics